Led long-range planning team for $2.6bn biopharmaceutical company focused on reducing cardiovascular events and eradicating infectious diseases• Initiated rebuild of the long-range planning model for CEO and CFO that is the basis for the $500mm global budget, valuation and portfolio management decisions• Conducted analysis for CFO to assess strategic options which resulted in the divestment of three hemostasis and three cardiovascular products with a total value of $1.2bn• Interim leader of Investor Relations reporting to CFO; achieved two equity research target price increases and three new investors to top 20 shareholders• Directed the standardization of forecast methods and expense templates to streamline the planning process, which reduced model update time by two days each quarter• Selected as one of four mentors to teach six summer associates about the drug development process, acute care space and epidemiology of our products• Assisted Business Development team with incoming due diligence requests for a potential cardiovascular partnership as well as surgical and infectious disease product divestments

Led valuation piece of due diligence for over 20 potential transactions; completed nine transactions in the cardiovascular, infectious disease and surgical spaces valued at $1.7bn• Analyzed five year global product operating expenses and commercialization plans; built prioritization schedule for CEO, CFO and CAO which saved $30mm annually• Performed initial screening on potential transactions and partnerships; assessed over 200 opportunities and recommended 33 for additional diligence to CFO